The Evidence for Symptomatic Treatments in ALS
The Evidence for Symptomatic Treatments in ALS
Riluzole remains the only disease-modifying therapy proven effective in ALS. Mean survival benefit from meta-analysis of RCTs is 2–3 months. Riluzole is generally well tolerated; monitoring of full blood count and liver function is required.
Disease-modifying Treatment
Riluzole remains the only disease-modifying therapy proven effective in ALS. Mean survival benefit from meta-analysis of RCTs is 2–3 months. Riluzole is generally well tolerated; monitoring of full blood count and liver function is required.
Source...